Statin Therapy in Acute Respiratory Distress Syndrome

Statin therapy, through inhibition of HMG-CoA reductase, exerts pleiotropic effects beyond lipid lowering, including attenuation of endothelial dysfunction, reduction of pro-inflammatory cytokines and modulation of immune cell activity. In the setting of acute respiratory distress syndrome (ARDS), these actions may stabilise the alveolar–capillary barrier, limit neutrophil-mediated injury and improve oxygenation. Clinical investigations have, however, yielded heterogeneous results, reflecting the complexity of ARDS as a syndrome with multiple aetiologies and host responses. Subphenotype analyses suggest that patient characteristics – such as baseline cholesterol levels and biomarkers of inflammasome activation – influence response to different statins. Cost-utility assessments indicate that, even in the absence of clear survival benefit, some statins may provide quality-adjusted life-year gains at acceptable incremental costs. Ongoing efforts aim to define which patient subgroups derive net benefit and to establish optimal timing, dosing and choice of statin in ARDS management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Statin Therapy in Acute Respiratory Distress Syndrome publication trend

The graph below shows the total number of articles in statin therapy in acute respiratory distress syndrome across all publications each year (not limited to Nature Index journals).

Technical terms

Acute Respiratory Distress Syndrome (ARDS): A rapidly progressive inflammatory lung injury characterised by diffuse alveolar damage, severe hypoxaemia and non-cardiogenic pulmonary oedema.

HMG-CoA Reductase: The rate-limiting enzyme in cholesterol biosynthesis inhibited by statins, leading to reduced mevalonate production and downstream anti-inflammatory effects.

Inflammasome: A multiprotein complex within immune cells that activates caspase-1, resulting in maturation and release of pro-inflammatory cytokines such as interleukin-1β and interleukin-18.

Subphenotype: A clinically or biologically defined subgroup within a heterogeneous syndrome, distinguished by specific biomarkers, physiological parameters or treatment responses.

References

1. Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials. Critical Care (2023).
2. Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. Critical Care (2022).
3. Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial. Critical Care (2017).